<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629104</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-AS</org_study_id>
    <nct_id>NCT05629104</nct_id>
  </id_info>
  <brief_title>Prediction of Long-term Outcome in Aortic Stenosis After Valve Intervention</brief_title>
  <official_title>Biological Valve Prosthesis in Aortic Stenosis - Imaging, Biomarkers, Physical Performance and Patient Related Factors Predictive to Long-term Outcome (Bio-AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe aortic stenosis accepted for transcatheter intervention or open surgery&#xD;
      are included before the intervention, and then followed up with clinical visits during the&#xD;
      first year after intervention. Imaging with echocardiography and computed tomography (CT) are&#xD;
      performed together with additional imaging with magnetic resonance imaging (MRI) and Positron&#xD;
      emissions tomography (PET)-CT in a subgroup of the study population. Blood samples, physical&#xD;
      performance and questionnaires with focus on frailty and heart failure are also collected at&#xD;
      each visit. A follow up with information of the outcomes after 2-5 years will be performed&#xD;
      through national registries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Semiquantitative assessment of protein levels associated with myocardial performance</measure>
    <time_frame>One year after intervention.</time_frame>
    <description>Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imaging parameters associated with clinical outcome after intervention</measure>
    <time_frame>One year after intervention</time_frame>
    <description>Global longitudinal strain (%) of the right and left ventricle. The clinical outcome defined as a combination of mortality and hospitalization of heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semiquantitative assessment of protein levels associated with myocardial performance associated with clinical outcome after intervention</measure>
    <time_frame>Two years after intervention</time_frame>
    <description>Level of normalized protein expression (NPX) in plasma, assessed by a multiplex proximity extension assay panel (Olink Bioscience, Uppsala, Sweden). The clinical outcome defined as a combination of mortality and hospitalization for heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Imaging parameters associated with clinical outcome after intervention</measure>
    <time_frame>Two years after intervention</time_frame>
    <description>Volumes of the right and left ventricle (mL/m2). The clinical outcome defined as a combination of mortality and hospitalization for heart failure.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Preserved heart function</arm_group_label>
    <description>The group will be defined as preserved left ventricular ejection fraction (LVEF) with and without hypertrophy and with and without reduced global longitudinal strain (GLS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduced heart function</arm_group_label>
    <description>The group will be defined as reduced LVEF</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention since it is an observational study patients are treated according to clinical praxis</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Preserved heart function</arm_group_label>
    <arm_group_label>Reduced heart function</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients accepted for aortic valve intervention due to aortic stenosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Accepted for aortic valve intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No able to follow the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christina Christersson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VO hj√§rt-lungmedicin och klinisk fysiologi Akademiska Sjukhuset</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Christersson, MD PhD</last_name>
    <phone>+46186119068</phone>
    <email>christina.christersson@medsci.uu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of cardiology Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Christersson, MD PhD</last_name>
      <phone>+46186119068</phone>
      <email>christina.christersson@medsci.uu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

